https://m2.mtmt.hu/ hun 2026-09-21 15:58 JournalArticle 35663269 VALIDATED true Funding Agency and Grant Number: Semmelweis University Funding text: Acknowledgements The authors gratefully acknowledge Semmelweis University for the support, which made the research and publication of the results possible. 0 false 2026-09-05T14:05:04.560+0000 2026-06-18T17:18:31.072+0000 2025-01-06T09:50:44.731+0000 true 10015206 Áncsán Gizella /api/admin/10015206 Admin Áncsán Gizella (SE admin) true 10015206 2026-08-12T06:44:33.951+0000 2026-08-12T06:43:57.299+0000 2025-09-15T10:01:07.500+0000 true 10015206 Áncsán Gizella /api/admin/10015206 Admin Áncsán Gizella (SE admin) true 10015206 true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 1134514 Survey paper true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/1134514 Összefoglaló cikk SubType Összefoglaló cikk (Folyóiratcikk) 102 true 1134514 true 1 /api/category/1 Category Tudományos true 1 Bednárik, Dániel Steve true true /api/journal/20089619 REVIEWED LANCET REGIONAL HEALTH - EUROPE 2666-7762 true false false 20089619 true 2666-7762 Journal FOREIGN 49 101151 101151 14 2025 true true 2025 true true true false true false GOLD 2026-09-05 true https://doi.org/10.1016/j.lanepe.2024.101151 24 0 24 23 2 24 24 20 22 23 23 22 22 23 1 0 24 23 24 23 0 3 3 Folyóiratcikk Journal Article 24 24 Könyvrészlet Chapter in Book 25 0 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2025 0 11 11 11 11 2026 0 13 12 13 12 D1 false 10023767 false false false 2025-02-17T11:53:55.039+0000 Biofizikai és Sugárbiológiai Intézet (SE / AOK / I); Egészségtudományi Kar (SE); Morfológiai és Fiziológiai Tanszék (SE / ETK2007); Pankreász Betegségek Intézete (SE / AOK / K); Reumatológiai és Immunológiai Klinika (SE / KKP); Transzlációs Medicina Intézet (PTE / ÁOK); Transzlációs Medicina Központ (SE / KSZE) 11 46 7 12 0 true Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 122575848 /api/authorship/122575848 Bednárik, Dániel Steve [Bednárik, Dániel Steve (Gasztroenterológi...), szerző] Transzlációs Medicina Központ (SE / KSZE) 1 0.083 true false false Author 10094929 /api/author/10094929 Bednárik Dániel Steve (Gasztroenterológia, Gyermekgyógyászat) Bednárik Dániel Steve true true Bednárik Dániel Steve true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 122575849 /api/authorship/122575849 Földvári-Nagy, Kincső Csepke [Földvári-Nagy, Kincső Csepke (biológia), szerző] Egészségtudományi Kar (SE) 2 0.083 false false false Author 10101786 /api/author/10101786 Földvári-Nagy Kincső Csepke (biológia) Földvári-Nagy Kincső Csepke true true Földvári-Nagy Kincső Csepke true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 122575850 /api/authorship/122575850 Simon, Viktor [Simon, Viktor (Egészségtudomány), szerző] Egészségtudományi Kar (SE) 3 0.083 false false false Author 10100336 /api/author/10100336 Simon Viktor (Egészségtudomány) Simon Viktor true true Simon Viktor true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 122575851 /api/authorship/122575851 Rancz, Anett [Rancz, Anett (Mikroszkópos colitis), szerző] Transzlációs Medicina Központ (SE / KSZE); Reumatológiai és Immunológiai Klinika (SE / KKP) 4 0.083 false false false Author 10085074 /api/author/10085074 Rancz Anett (Mikroszkópos colitis) Rancz Anett true true Rancz Anett true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 122575852 /api/authorship/122575852 Gede, Noémi [Gede, Noémi (Egészségtudomány), szerző] Transzlációs Medicina Központ (SE / KSZE) 5 0.083 false false false Author 10048360 /api/author/10048360 Gede Noémi (Egészségtudomány) Gede Noémi true 10048360 true Gede Noémi true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 122575853 /api/authorship/122575853 Veres, Dániel Sándor [Veres, Dániel (Biofizika), szerző] Biofizikai és Sugárbiológiai Intézet (SE / AOK / I); Transzlációs Medicina Központ (SE / KSZE) 6 0.083 false false false Author 10031347 /api/author/10031347 Veres Dániel (Biofizika) Veres Dániel true 10031347 true Veres Dániel Sándor true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 122575854 /api/authorship/122575854 Paraskevopoulos, Panagiotis [Paraskevopoulos, Panagiotis (Radiology), szerző] Transzlációs Medicina Központ (SE / KSZE) 7 0.083 false false false Author 10085993 /api/author/10085993 Paraskevopoulos Panagiotis (Radiology) Paraskevopoulos Panagiotis true true Paraskevopoulos Panagiotis true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 122575855 /api/authorship/122575855 Schnabel, Tamás 8 0.083333336 false false false Schnabel Tamás true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 122575856 /api/authorship/122575856 Erőss, Bálint [Erőss, Bálint Mihály (Gasztroenterológia), szerző] Pankreász Betegségek Intézete (SE / AOK / K); Transzlációs Medicina Központ (SE / KSZE); Transzlációs Medicina Intézet (PTE / ÁOK) 9 0.083 false false false Author 10064235 /api/author/10064235 Erőss Bálint Mihály (Gasztroenterológia) Erőss Bálint Mihály true 10064235 true Erőss Bálint true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 122575857 /api/authorship/122575857 Hegyi, Péter [Hegyi, Péter (Gasztroenterológia), szerző] Pankreász Betegségek Intézete (SE / AOK / K); Transzlációs Medicina Központ (SE / KSZE); Transzlációs Medicina Intézet (PTE / ÁOK) 10 0.083 false false false Author 10002629 /api/author/10002629 Hegyi Péter (Gasztroenterológia) Hegyi Péter true 10002629 true Hegyi Péter true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 122575858 /api/authorship/122575858 Lenti, Katalin** [Földvári-Nagy Lászlóné Lenti, Katalin (élettan-biokémia), szerző] Morfológiai és Fiziológiai Tanszék (SE / ETK2007) 11 0.083 false true false Author 10023767 /api/author/10023767 Földvári-Nagy Lászlóné Lenti Katalin (élettan-biokémia) Földvári-Nagy Lászlóné Lenti Katalin true 10023767 true Lenti Katalin true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 122575859 /api/authorship/122575859 Földvári-Nagy, László ✉ [Földvári-Nagy, László (biológia), szerző] Morfológiai és Fiziológiai Tanszék (SE / ETK2007) 12 0.083 false true true Author 10045537 /api/author/10045537 Földvári-Nagy László (biológia) Földvári-Nagy László true 10045537 true Földvári-Nagy László true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 28154400 /api/publicationidentifier/28154400 DOI: 10.1016/j.lanepe.2024.101151 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true GOLD true IDENTICAL 10.1016/j.lanepe.2024.101151 https://doi.org/10.1016/j.lanepe.2024.101151 false true PublicationIdentifier 28677248 /api/publicationidentifier/28677248 WoS: 001435988400001 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 001435988400001 https://www.webofscience.com/wos/woscc/full-record/001435988400001 true true PublicationIdentifier 28509838 /api/publicationidentifier/28509838 Scopus: 85211330692 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 85211330692 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85211330692 false true PublicationIdentifier 28587824 /api/publicationidentifier/28587824 PubMed: 39989875 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 39989875 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=39989875&dopt=Abstract false true Keyword 3375201 /api/keyword/3375201 [Meta-analysis] true true SjrRating 11617772 /api/sjrrating/11617772 sjr:D1 (2025) Scopus - Public Health, Environmental and Occupational Health LANCET REGIONAL HEALTH - EUROPE 2666-7762 6 0.0 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 2739 /api/classificationexternal/2739 Scopus - Public Health, Environmental and Occupational Health true 2739 true D1 DIRECT true true Reference 61191763 /api/reference/61191763 1. Lawson 2016: Anaerobe Reclassi fi cation of Clostridium dif fi cile as Clostridioides dif fi cile (Hall and vot 1938 O ’ Toole 1935) Pre., 40, p. 95 1 false true Reference 61191764 /api/reference/61191764 2. Mada 2023: Clostridioides difficile infection 2 false true Reference 61191765 /api/reference/61191765 3. Fu 2021: Epidemiology of community-acquired and recurrent Clostridioides difficile infection., Therap Adv Gastroenterol, 14, p. 1, DOI: 10.1177/17562848211016248 3 10.1177/17562848211016248 false true Reference 61191766 /api/reference/61191766 4. Czepiel 2019: Clostridium difficile infection: reviewp. 1211 4 false true Reference 61191767 /api/reference/61191767 5. Leffler 2016: Clostridium difficile infection., Emerg Infect, 10, p. 265 5 false true Reference 61191768 /api/reference/61191768 6. Johnson 1990: Prospective, controlled study of Vinyl Glove use to interrupt Clostridium difficile nosocomial transmission., Am J Med, 88, p. 137, DOI: 10.1016/0002-9343(90)90462-M 6 10.1016/0002-9343(90)90462-M false true Reference 61191769 /api/reference/61191769 7. Johnson 2021: Clinical practice guideline by the infectious diseases society of America (IDSA) and society for healthcare epidemiology of America (SHEA): 2021 focused update guidelines on management of clostridioides difficile infection in adults., Clin Infect Dis, 73, p. e1029, DOI: 10.1093/cid/ciab549 7 10.1093/cid/ciab549 false true Reference 61191770 /api/reference/61191770 8. van Prehn 2021: European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults., Clin Microbiol Infect, 27, p. S1, DOI: 10.1016/j.cmi.2021.09.038 8 10.1016/j.cmi.2021.09.038 false true Reference 61191771 /api/reference/61191771 9. Beinortas 2018: Comparative efficacy of treatments for Clostridium difficile infection: a systematic review and network meta-analysis., Lancet Infect Dis, 18, p. 1035, DOI: 10.1016/S1473-3099(18)30285-8 9 10.1016/S1473-3099(18)30285-8 false true Reference 61191772 /api/reference/61191772 10. Dembrovszky 2021: Fecal microbiota transplantation may be the best option in treating multiple clostridioides difficile infection: a network meta-analysis., Infect Dis Ther, 10, p. 201, DOI: 10.1007/s40121-020-00356-9 10 10.1007/s40121-020-00356-9 false true Reference 61191773 /api/reference/61191773 11. Rokkas 2019: A network meta-analysis of randomized controlled trials exploring the role of fecal microbiota transplantation in recurrent Clostridium difficile infection., United Eur Gastroenterol J, 7, p. 1051, DOI: 10.1177/2050640619854587 11 10.1177/2050640619854587 false true Reference 61191774 /api/reference/61191774 12. Sridharan 2019: Which antimicrobial agent is likely to be the best for treating Clostridium difficile infections? A bayesian network meta-analysis of randomized clinical trials., Drug Res, 69, p. 194, DOI: 10.1055/a-0645-1169 12 10.1055/a-0645-1169 false true Reference 61191775 /api/reference/61191775 13. Alhifany 2019: Comparing the efficacy and safety of faecal microbiota transplantation with bezlotoxumab in reducing the risk of recurrent Clostridium difficile infections: a systematic review and Bayesian network meta-analysis of randomised controlled trials., BMJ Open, 9, p. 1, DOI: 10.1136/bmjopen-2019-031145 13 10.1136/bmjopen-2019-031145 false true Reference 61191776 /api/reference/61191776 14. Page 2021: The PRISMA 2020 statement: an updated guideline for reporting systematic reviews., Int J Surg, 88, DOI: 10.1016/j.ijsu.2021.105906 14 10.1016/j.ijsu.2021.105906 false true Reference 61191777 /api/reference/61191777 15. Hutton 2015: The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations., Ann Intern Med, 162, p. 777, DOI: 10.7326/M14-2385 15 10.7326/M14-2385 false true Reference 61191778 /api/reference/61191778 16. Higgins 2008: Cochrane handbook for systematic reviews of interventionsp. S38 16 false true Reference 61191779 /api/reference/61191779 17. McDonald 2018: Clinical practice guidelines for clostridium difficile infection in adults and children: 2017 update by the infectious diseases society of America (IDSA) and society for healthcare epidemiology of America (SHEA)., Clin Infect Dis, 66, p. 987, DOI: 10.1093/cid/ciy149 17 10.1093/cid/ciy149 false true Reference 61191780 /api/reference/61191780 18. Surawicz 2013: Guidelines for diagnosis, treatment, and prevention of clostridium difficile infections., Am J Gastroenterol, 108, p. 478, DOI: 10.1038/ajg.2013.4 18 10.1038/ajg.2013.4 false true Reference 61191781 /api/reference/61191781 19. Ouzzani 2016: Rayyan-a web and mobile app for systematic reviews., Syst Rev, 5, p. 1, DOI: 10.1186/s13643-016-0384-4 19 10.1186/s13643-016-0384-4 false true Reference 61191782 /api/reference/61191782 20. Cohen 1960: A coefficient of agreement for nominal scales., Educ Psychol Meas, 20, p. 37, DOI: 10.1177/001316446002000104 20 10.1177/001316446002000104 false true Reference 61191783 /api/reference/61191783 21. Schünemann 2019: Interpreting results and drawing conclusions., Cochrane Handb Syst Rev Interv, p. 403 21 false true Reference 61191784 /api/reference/61191784 22. Papakonstantinou 2020: CINeMA: software for semiautomated assessment of the confidence in the results of network meta-analysis., Campbell Syst Rev, 16, p. 1 22 false true Reference 61191785 /api/reference/61191785 23. Rücker 2015: Ranking treatments in frequentist network meta-analysis works without resampling methods., BMC Med Res Methodol, 15, p. 58, DOI: 10.1186/s12874-015-0060-8 23 10.1186/s12874-015-0060-8 false true Reference 61191786 /api/reference/61191786 24. Harrer 2021: Doing meta-analysis with R: a hands-on guide 24 false true Reference 61191787 /api/reference/61191787 25. Chaimani 2012: Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions., Res Synth Methods, 3, p. 161, DOI: 10.1002/jrsm.57 25 10.1002/jrsm.57 false true Reference 61191788 /api/reference/61191788 26. 2024: R: a language and environment for StatisticalComputing 26 false true Reference 61191789 /api/reference/61191789 27. Balduzzi 2023: Netmeta: an R package for network meta-analysis using frequentist methods., J Stat Softw, 106 27 false true Reference 61191790 /api/reference/61191790 28. Beliveau 2022: BUGSnet: Bayesian network meta-analyses in compliance with best practice and reporting guidelines 28 false true Reference 61191791 /api/reference/61191791 29. Schwarzer 29 false true Reference 61191792 /api/reference/61191792 30. Viechtbauer 30 false true Reference 61191793 /api/reference/61191793 31. Cuijpers 2024: Companion r package for the guide doing meta-analysis in R 31 false true Reference 61191794 /api/reference/61191794 32. Page 2021: The PRISMA 2020 statement: an updated guideline for reporting systematic reviews., BMJ, 372, p. n71, DOI: 10.1136/bmj.n71 32 10.1136/bmj.n71 false true Reference 61191795 /api/reference/61191795 33. van Nood 2013: Duodenal infusion of donor feces for recurrent Clostridium difficile., N Engl J Med, 368, p. 407, DOI: 10.1056/NEJMoa1205037 33 10.1056/NEJMoa1205037 false true Reference 61191796 /api/reference/61191796 34. Baunwall 2022: Faecal microbiota transplantation for first or second Clostridioides difficile infection (EarlyFMT): a randomised, double-blind, placebo-controlled trial., Lancet Gastroenterol Hepatol, 7, p. 1083, DOI: 10.1016/S2468-1253(22)00276-X 34 10.1016/S2468-1253(22)00276-X false true Reference 61191797 /api/reference/61191797 35. Feuerstadt 2022: SER-109, an oral microbiome therapy for recurrent clostridioides difficile infection., N Engl J Med, 386, p. 220, DOI: 10.1056/NEJMoa2106516 35 10.1056/NEJMoa2106516 false true Reference 61191798 /api/reference/61191798 36. Guery 2018: Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial., Lancet Infect Dis, 18, p. 296, DOI: 10.1016/S1473-3099(17)30751-X 36 10.1016/S1473-3099(17)30751-X false true Reference 61191799 /api/reference/61191799 37. Hvas 2019: Fecal microbiota transplantation is superior to fidaxomicin for treatment of recurrent Clostridium difficile infection., Gastroenterology, 156, p. 1324, DOI: 10.1053/j.gastro.2018.12.019 37 10.1053/j.gastro.2018.12.019 false true Reference 61191800 /api/reference/61191800 38. Housman 2016: Assessment of Clostridium difficile burden in patients over time with first episode infection following fidaxomicin or vancomycin., Infect Control Hosp Epidemiol, 37, p. 215, DOI: 10.1017/ice.2015.270 38 10.1017/ice.2015.270 false true Reference 61191801 /api/reference/61191801 39. Young 1985: Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin., Gastroenterology, 89, p. 1038, DOI: 10.1016/0016-5085(85)90206-9 39 10.1016/0016-5085(85)90206-9 false true Reference 61191802 /api/reference/61191802 40. Louie 2011: Fidaxomicin versus vancomycin for Clostridium difficile infection., N Engl J Med, 364, p. 422, DOI: 10.1056/NEJMoa0910812 40 10.1056/NEJMoa0910812 false true Reference 61191803 /api/reference/61191803 41. Wullt 2004: A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea., J Antimicrob Chemother, 54, p. 211, DOI: 10.1093/jac/dkh278 41 10.1093/jac/dkh278 false true Reference 61191804 /api/reference/61191804 42. Teasley 1983: Prospective randomised trial of metronidazole versus vancomycin for clostridium-difficile-associated diarrhoea and colitis., Lancet, 322, p. 1043, DOI: 10.1016/S0140-6736(83)91036-X 42 10.1016/S0140-6736(83)91036-X false true Reference 61191805 /api/reference/61191805 43. Cornely 2012: Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial., Lancet Infect Dis, 12, p. 281, DOI: 10.1016/S1473-3099(11)70374-7 43 10.1016/S1473-3099(11)70374-7 false true Reference 61191806 /api/reference/61191806 44. Lagrotteria 2006: Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea., Clin Infect Dis, 43, p. 547, DOI: 10.1086/506354 44 10.1086/506354 false true Reference 61191807 /api/reference/61191807 45. Boix 2017: Primary outcomes from a phase 3, randomized, double-blind, active-controlled trial of surotomycin in subjects with Clostridium difficile infection., Open Forum Infect Dis, 4, p. 1, DOI: 10.1093/ofid/ofw275 45 10.1093/ofid/ofw275 false true Reference 61191808 /api/reference/61191808 46. Mikamo 2018: Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan., J Infect Chemother, 24, p. 744, DOI: 10.1016/j.jiac.2018.05.010 46 10.1016/j.jiac.2018.05.010 false true Reference 61191809 /api/reference/61191809 47. Musher 2009: Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study., Clin Infect Dis, 48, p. 41, DOI: 10.1086/596552 47 10.1086/596552 false true Reference 61191810 /api/reference/61191810 48. Rode 2021: Randomised clinical trial: a 12-strain bacterial mixture versus faecal microbiota transplantation versus vancomycin for recurrent Clostridioides difficile infections., Aliment Pharmacol Ther, 53, p. 999, DOI: 10.1111/apt.16309 48 10.1111/apt.16309 false true Reference 61191811 /api/reference/61191811 49. Thabit 2016: A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin., Ann Clin Microbiol Antimicrob, 15, p. 1, DOI: 10.1186/s12941-016-0140-6 49 10.1186/s12941-016-0140-6 false true Reference 61191812 /api/reference/61191812 50. Wenisch 1996: Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea., Clin Infect Dis, 22, p. 813, DOI: 10.1093/clinids/22.5.813 50 10.1093/clinids/22.5.813 false true Reference 61191813 /api/reference/61191813 51. Zar 2007: A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity., Clin Infect Dis, 45, p. 302, DOI: 10.1086/519265 51 10.1086/519265 false true Reference 61191814 /api/reference/61191814 52. Musher 2006: Nitazoxanide for the treatment of Clostridium difficile colitis: commentary., Infect Dis Clin Pract, 14, p. 255 52 false true Reference 61191815 /api/reference/61191815 53. Okhuysen 2024: A randomized, double-blind, phase 3 safety and efficacy study of ridinilazole versus vancomycin for treatment of clostridioides difficile infection: clinical outcomes with microbiome and metabolome correlates of response., Clin Infect Dis, 78, p. 1462, DOI: 10.1093/cid/ciad792 53 10.1093/cid/ciad792 false true Reference 61191816 /api/reference/61191816 54. Rao 2024: An open-label, randomized trial comparing fidaxomicin with oral vancomycin for the treatment of clostridioides difficile infection in hospitalized patients receiving concomitant antibiotics for concurrent infections., Clin Infect Dis, 78, p. 277, DOI: 10.1093/cid/ciad606 54 10.1093/cid/ciad606 false true Reference 61191817 /api/reference/61191817 55. Camacho-Ortiz 2017: Randomized clinical trial to evaluate the effect of fecal microbiota transplant for initial clostridium difficile infection in intestinal microbiome., PLoS One, 12, p. 1, DOI: 10.1371/journal.pone.0189768 55 10.1371/journal.pone.0189768 false true Reference 61191818 /api/reference/61191818 56. Cammarota 2015: Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection., Aliment Pharmacol Ther, 41, p. 835, DOI: 10.1111/apt.13144 56 10.1111/apt.13144 false true Reference 61191819 /api/reference/61191819 57. Daley 2017: Surotomycin versus vancomycin in adults with Clostridium difficile infection: primary clinical outcomes from the second pivotal, randomized, double-blind, Phase 3 trial., J Antimicrob Chemother, 72, p. 3462, DOI: 10.1093/jac/dkx299 57 10.1093/jac/dkx299 false true Reference 61191820 /api/reference/61191820 58. De Lalla 1992: Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea., Antimicrob Agents Chemother, 36, p. 2192, DOI: 10.1128/AAC.36.10.2192 58 10.1128/AAC.36.10.2192 false true Reference 61191821 /api/reference/61191821 59. Johnson 1992: Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole: a randomized, placebo-controlled trial., Ann Intern Med, 117, p. 297, DOI: 10.7326/0003-4819-117-4-297 59 10.7326/0003-4819-117-4-297 false true Reference 61191822 /api/reference/61191822 60. Johnson 2014: Vancomycin, metronidazole, or tolevamer for clostridium difficile infection: results from two multinational, randomized, controlled trials., Clin Infect Dis, 59, p. 345, DOI: 10.1093/cid/ciu313 60 10.1093/cid/ciu313 false true Reference 61191823 /api/reference/61191823 61. Dudley 1986: Oral bacitracin vs vancomycin therapy for Clostridium difficile—induced diarrhea: a randomized double-blind trial., Arch Intern Med, 146, p. 1101, DOI: 10.1001/archinte.1986.00360180083015 61 10.1001/archinte.1986.00360180083015 false true Reference 61191824 /api/reference/61191824 62. Hota 2017: Oral vancomycin followed by fecal transplantation versus tapering oral vancomycin treatment for recurrent clostridium difficile infection: an open-label, randomized controlled trial., Clin Infect Dis, 64, p. 265, DOI: 10.1093/cid/ciw731 62 10.1093/cid/ciw731 false true Reference 61191825 /api/reference/61191825 63. Garza-González 2019: Intestinal microbiome changes in fecal microbiota transplant (FMT) vs. FMT enriched with lactobacillus in the treatment of recurrent clostridioides difficile infection., Can J Gastroenterol Hepatol, 2019, DOI: 10.1155/2019/4549298 63 10.1155/2019/4549298 false true Reference 61191826 /api/reference/61191826 64. Allegretti 2024: Outcomes after fecal microbiota transplantation in combination with bezlotoxumab for inflammatory bowel disease and recurrent clostridioides difficile infection., Am J Gastroenterol, 119, p. 1433, DOI: 10.14309/ajg.0000000000002770 64 10.14309/ajg.0000000000002770 false true Reference 61191827 /api/reference/61191827 65. Allen 2013: Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial., Lancet, 382, p. 1249, DOI: 10.1016/S0140-6736(13)61218-0 65 10.1016/S0140-6736(13)61218-0 false true Reference 61191828 /api/reference/61191828 66. Beausoleil 2007: Effect of a fermented milk combining Lactobacillus acidophilus CL1285 and Lactobacillus casei in the prevention of antibiotic-associated diarrhea: a randomized, double-blind, placebo-controlled trial., Can J Gastroenterol, 21, p. 732, DOI: 10.1155/2007/720205 66 10.1155/2007/720205 false true Reference 61191829 /api/reference/61191829 67. Lewis 1998: The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhoea in elderly patients., J Infect, 36, p. 171 67 false true Reference 61191830 /api/reference/61191830 68. Morrow 2010: Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial., Am J Respir Crit Care Med, 182, p. 1058, DOI: 10.1164/rccm.200912-1853OC 68 10.1164/rccm.200912-1853OC false true Reference 61191831 /api/reference/61191831 69. Mullane 2019: A randomized, placebo-controlled trial of fidaxomicin for prophylaxis of Clostridium difficile-associated diarrhea in adults undergoing hematopoietic stem cell transplantation., Clin Infect Dis, 68, p. 196, DOI: 10.1093/cid/ciy484 69 10.1093/cid/ciy484 false true Reference 61191832 /api/reference/61191832 70. Nord 1997: Oral supplementation with lactic acid-producing bacteria during intake of clindamycin., Clin Microbiol Infect, 3, p. 124, DOI: 10.1111/j.1469-0691.1997.tb00262.x 70 10.1111/j.1469-0691.1997.tb00262.x false true Reference 61191833 /api/reference/61191833 71. Plummer 2004: Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea., Int Microbiol, 7, p. 59 71 false true Reference 61191834 /api/reference/61191834 72. Pozzoni 2012: Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial., Am J Gastroenterol, 107, p. 922, DOI: 10.1038/ajg.2012.56 72 10.1038/ajg.2012.56 false true Reference 61191835 /api/reference/61191835 73. Prasoon 2022: A randomized controlled trial to evaluate the use of probiotics in prevention of ventilator-associated pneumonia in critically Ill ICU patients., J Card Crit Care TSS, 6, p. 108, DOI: 10.1055/s-0042-1754161 73 10.1055/s-0042-1754161 false true Reference 61191836 /api/reference/61191836 74. Rajkumar 2020: Do probiotics prevent antibiotic-associated diarrhoea? Results of a multicentre randomized placebo-controlled trial., J Hosp Infect, 105, p. 280, DOI: 10.1016/j.jhin.2020.01.018 74 10.1016/j.jhin.2020.01.018 false true Reference 61191837 /api/reference/61191837 75. Rauseo 2022: A randomized controlled trial of Lactobacillus rhamnosus GG on antimicrobial-resistant organism colonization., Infect Control Hosp Epidemiol, 43, p. 167, DOI: 10.1017/ice.2021.94 75 10.1017/ice.2021.94 false true Reference 61191838 /api/reference/61191838 76. Sadahiro 2014: Comparison between oral antibiotics and probiotics as bowel preparation for elective colon cancer surgery to prevent infection: prospective randomized trial., Surg (United States), 155, p. 493 76 false true Reference 61191839 /api/reference/61191839 77. Can 2006: Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: a prospective study., Med Sci Monit, 12, p. 19 77 false true Reference 61191840 /api/reference/61191840 78. Surawicz 1989: Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study., Gastroenterology, 96, p. 981, DOI: 10.1016/0016-5085(89)91613-2 78 10.1016/0016-5085(89)91613-2 false true Reference 61191841 /api/reference/61191841 79. Surawicz 2000: The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii., Clin Infect Dis, 31, p. 1012, DOI: 10.1086/318130 79 10.1086/318130 false true Reference 61191842 /api/reference/61191842 80. Thomas 2001: Lack of effect of Lactobacillus GG on antibiotic-associated diarrhea: a randomized, placebo-controlled trial., Mayo Clin Proc, 76, p. 883, DOI: 10.1016/S0025-6196(11)62106-X 80 10.1016/S0025-6196(11)62106-X false true Reference 61191843 /api/reference/61191843 81. Tobar-Marcillo 2018: Metronidazole in the prevention of antibiotic-associated diarrhoea and Clostridium difficile infection in high-risk hospitalised patients., Gastroenterol Hepatol, 41, p. 362, DOI: 10.1016/j.gastrohep.2018.04.002 81 10.1016/j.gastrohep.2018.04.002 false true Reference 61191844 /api/reference/61191844 82. Laffan 2011: Lactoferrin for the prevention of post-antibiotic diarrhoea., J Heal Popul Nutr, 29, p. 547 82 false true Reference 61191845 /api/reference/61191845 83. Major 2019: Follow-on RifAximin for the Prevention of recurrence following standard treatment of Infection with Clostridium Difficile (RAPID): a randomised placebo controlled trial., Gut, 68, p. 1224, DOI: 10.1136/gutjnl-2018-316794 83 10.1136/gutjnl-2018-316794 false true Reference 61191846 /api/reference/61191846 84. Wong 2014: A Lactobacillus casei Shirota probiotic drink reduces antibiotic-associated diarrhoea in patients with spinal cord injuries: a randomised controlled trial., Br J Nutr, 111, p. 672, DOI: 10.1017/S0007114513002973 84 10.1017/S0007114513002973 false true Reference 61191847 /api/reference/61191847 85. Wilcox 2017: Bezlotoxumab for preventing recurrent Clostridium difficile infections., N Engl J Med, 70, p. 422 85 false true Reference 61191848 /api/reference/61191848 86. Saviano 2024: The efficacy of a mix of probiotics (limosilactobacillus reuteri LMG P-27481 and lacticaseibacillus rhamnosus GG ATCC 53103) in preventing antibiotic-associated diarrhea and Clostridium difficile infection in hospitalized patients: single-center, open-lab., Microorganisms, 12, DOI: 10.3390/microorganisms12010198 86 10.3390/microorganisms12010198 false true Reference 61191849 /api/reference/61191849 87. de Bruyn 2021: Safety, immunogenicity, and efficacy of a Clostridioides difficile toxoid vaccine candidate: a phase 3 multicentre, observer-blind, randomised, controlled trial., Lancet Infect Dis, 21, p. 252, DOI: 10.1016/S1473-3099(20)30331-5 87 10.1016/S1473-3099(20)30331-5 false true Reference 61191850 /api/reference/61191850 88. Ehrhardt 2016: Saccharomyces boulardii to prevent antibiotic-associated diarrhea: a randomized, double-masked, placebo-controlled trial., Open Forum Infect Dis, 3, p. 1, DOI: 10.1093/ofid/ofw011 88 10.1093/ofid/ofw011 false true Reference 61191851 /api/reference/61191851 89. Garey 2011: A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection., J Antimicrob Chemother, 66, p. 2850, DOI: 10.1093/jac/dkr377 89 10.1093/jac/dkr377 false true Reference 61191852 /api/reference/61191852 90. Hickson 2007: Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial., Br Med J, 335, p. 80, DOI: 10.1136/bmj.39231.599815.55 90 10.1136/bmj.39231.599815.55 false true Reference 61191853 /api/reference/61191853 91. Johnson 2020: Effectiveness of oral vancomycin for prevention of healthcare facility-onset clostridioides difficile infection in targeted patients during systemic antibiotic exposure., Clin Infect Dis, 71, p. 1133, DOI: 10.1093/cid/ciz966 91 10.1093/cid/ciz966 false true Reference 61191854 /api/reference/61191854 92. Khanna 2022: Efficacy and safety of RBX2660 in PUNCH CD3, a phase III, randomized, double-blind, placebo-controlled trial with a bayesian primary analysis for the prevention of recurrent clostridioides difficile infection., Drugs, 82, p. 1527, DOI: 10.1007/s40265-022-01797-x 92 10.1007/s40265-022-01797-x false true Reference 61191855 /api/reference/61191855 93. Lewis 2005: Effect of the prebiotic oligofructose on relapse of Clostridium difficile-associated diarrhea: a randomized, controlled study., Clin Gastroenterol Hepatol, 3, p. 442, DOI: 10.1016/S1542-3565(04)00677-9 93 10.1016/S1542-3565(04)00677-9 false true Reference 61191856 /api/reference/61191856 94. Jiang 2018: Safety and preliminary efficacy of orally administered lyophilized fecal microbiota product compared with frozen product given by enema for recurrent Clostridium difficile infection: a randomized clinical trial., PLoS One, 13, p. 1, DOI: 10.1371/journal.pone.0205064 94 10.1371/journal.pone.0205064 false true Reference 61191857 /api/reference/61191857 95. Youngster 2014: Fecal microbiota transplant for relapsing clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study., Clin Infect Dis, 58, p. 1515, DOI: 10.1093/cid/ciu135 95 10.1093/cid/ciu135 false true Reference 61191858 /api/reference/61191858 96. Ianiro 2018: Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infection—single versus multiple infusions., Aliment Pharmacol Ther, 48, p. 152, DOI: 10.1111/apt.14816 96 10.1111/apt.14816 false true Reference 61191859 /api/reference/61191859 97. Jiang 2017: Randomised clinical trial: faecal microbiota transplantation for recurrent Clostridum difficile infection—fresh, or frozen, or lyophilised microbiota from a small pool of healthy donors delivered by colonoscopy., Aliment Pharmacol Ther, 45, p. 899, DOI: 10.1111/apt.13969 97 10.1111/apt.13969 false true Reference 61191860 /api/reference/61191860 98. Lee 2016: Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent clostridium difficile infection a randomized clinical trial., -J Am Med Assoc, 315, p. 142, DOI: 10.1001/jama.2015.18098 98 10.1001/jama.2015.18098 false true Reference 61191861 /api/reference/61191861 99. Kao 2017: Effect of oral capsule– vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection: a randomized clinical trial., -J Am Med Assoc, 318, p. 1985, DOI: 10.1001/jama.2017.17077 99 10.1001/jama.2017.17077 false true Reference 61191862 /api/reference/61191862 100. Finegold 2004: In vitro activities of OPT-80 and comparator drugs against intestinal bacteria., Antimicrob Agents Chemother, 48, p. 4898, DOI: 10.1128/AAC.48.12.4898-4902.2004 100 10.1128/AAC.48.12.4898-4902.2004 false true Reference 61191863 /api/reference/61191863 101. Ackermann 2004: In vitro activity of OPT-80 against Clostridium difficile., Antimicrob Agents Chemother, 48, p. 2280, DOI: 10.1128/AAC.48.6.2280-2282.2004 101 10.1128/AAC.48.6.2280-2282.2004 false true Reference 61191864 /api/reference/61191864 102. Hecht 2007: In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004., Antimicrob Agents Chemother, 51, p. 2716, DOI: 10.1128/AAC.01623-06 102 10.1128/AAC.01623-06 false true Reference 61191865 /api/reference/61191865 103. Louie 2009: OPT-80 eliminates Clostridium difficile and is sparing of Bacteroides species during treatment of C. difficile infection., Antimicrob Agents Chemother, 53, p. 261, DOI: 10.1128/AAC.01443-07 103 10.1128/AAC.01443-07 false true Reference 61191866 /api/reference/61191866 104. Al-Nassir 2008: Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease., Antimicrob Agents Chemother, 52, p. 2403, DOI: 10.1128/AAC.00090-08 104 10.1128/AAC.00090-08 false true Reference 61191867 /api/reference/61191867 105. Bolton 1986: Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile., Gut, 27, p. 1169, DOI: 10.1136/gut.27.10.1169 105 10.1136/gut.27.10.1169 false true Reference 61191868 /api/reference/61191868 106. Tannock 2010: A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin., Microbiology, 156, p. 3354, DOI: 10.1099/mic.0.042010-0 106 10.1099/mic.0.042010-0 false true Reference 61191869 /api/reference/61191869 107. Baunwall 2021: The use of faecal microbiota transplantation (FMT) in Europe: a Europe-wide survey., Lancet Reg Health Eur, 9 107 false true Reference 61191870 /api/reference/61191870 108. Lee 2016: Surotomycin versus vancomycin for Clostridium difficile infection: phase 2, randomized, controlled, double-blind, non-inferiority, multicentre trial., J Antimicrob Chemother, 71, p. 2964, DOI: 10.1093/jac/dkw246 108 10.1093/jac/dkw246 false true Reference 61191871 /api/reference/61191871 109. Louie 2007: Results of a phase III study comparing tolevamer, vancomycin and metronidazole in Clostridium difficile-associated diarrhea (CDAD).Program and Abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 109 false true Reference 61191872 /api/reference/61191872 110. Bouza 2008: Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in the treatment of Clostridium difficile-associated diarrhoea.18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 110 false true Reference 61191873 /api/reference/61191873 111. Weiss 2009: Toxin-binding treatment for Clostridium difficile: a review including reports of studies with tolevamer., Int J Antimicrob Agents, 33, p. 4, DOI: 10.1016/j.ijantimicag.2008.07.011 111 10.1016/j.ijantimicag.2008.07.011 false true Reference 61191874 /api/reference/61191874 112. Davido 2017: Oral teicoplanin as an alternative first-line regimen in Clostridium difficile infection in elderly patients: a case series., Clin Drug Investig, 37, p. 699, DOI: 10.1007/s40261-017-0524-1 112 10.1007/s40261-017-0524-1 false true Reference 61191875 /api/reference/61191875 113. Popovic 2018: Oral teicoplanin versus oral vancomycin for the treatment of severe Clostridium difficile infection: a prospective observational study., Eur J Clin Microbiol Infect Dis, 37, p. 745, DOI: 10.1007/s10096-017-3169-3 113 10.1007/s10096-017-3169-3 false true Reference 61191876 /api/reference/61191876 114. Hegyi 2020: Academia europaea position paper on translational medicine: the cycle model for translating scientific results into community benefits., J Clin Med, 9 114 false true Reference 61191877 /api/reference/61191877 115. Hegyi 2021: Accelerating the translational medicine cycle: the Academia Europaea pilot., Nat Med, 27, p. 1316, DOI: 10.1038/s41591-021-01458-8 115 10.1038/s41591-021-01458-8 false true /api/publication/35663269 Bednárik Dániel Steve et al. Comparative effectiveness of different therapies for Clostridioides difficile infection in adults: a systematic review and network meta-analysis of randomized controlled trials. (2025) LANCET REGIONAL HEALTH - EUROPE 2666-7762 49<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" mtid="10094929"><a href="/gui2/?type=authors&mode=browse&sel=10094929" target="_blank">Bednárik Dániel Steve (<span class="authorship-author-name">Bednárik Dániel Steve</span> <span class="authorAux-mtmt"> Gasztroenterológia, Gyermekgyógyászat</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Központi Szervezeti Egységek (beleértve az Egyéb Szervezeti Egységeket)">KSZE</span>/Transzlációs Medicina Központ</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10101786"><a href="/gui2/?type=authors&mode=browse&sel=10101786" target="_blank">Földvári-Nagy Kincső Csepke (<span class="authorship-author-name">Földvári-Nagy Kincső Csepke</span> <span class="authorAux-mtmt"> biológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/Egészségtudományi Kar</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10100336"><a href="/gui2/?type=authors&mode=browse&sel=10100336" target="_blank">Simon Viktor (<span class="authorship-author-name">Simon Viktor</span> <span class="authorAux-mtmt"> Egészségtudomány</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/Egészségtudományi Kar</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10085074"><a href="/gui2/?type=authors&mode=browse&sel=10085074" target="_blank">Rancz Anett (<span class="authorship-author-name">Rancz Anett</span> <span class="authorAux-mtmt"> Mikroszkópos colitis</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Központi Szervezeti Egységek (beleértve az Egyéb Szervezeti Egységeket)">KSZE</span>/Transzlációs Medicina Központ; <span title="Semmelweis Egyetem">SE</span>/<span title="Klinikai Központ (karhoz nem tartozó egységek)">KKP</span>/Reumatológiai és Immunológiai Klinika</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10048360"><a href="/gui2/?type=authors&mode=browse&sel=10048360" target="_blank">Gede Noémi (<span class="authorship-author-name">Gede Noémi</span> <span class="authorAux-mtmt"> Egészségtudomány</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Központi Szervezeti Egységek (beleértve az Egyéb Szervezeti Egységeket)">KSZE</span>/Transzlációs Medicina Központ</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10031347"><a href="/gui2/?type=authors&mode=browse&sel=10031347" target="_blank">Veres Dániel Sándor (<span class="authorship-author-name">Veres Dániel</span> <span class="authorAux-mtmt"> Biofizika</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Biofizikai és Sugárbiológiai Intézet; <span title="Semmelweis Egyetem">SE</span>/<span title="Központi Szervezeti Egységek (beleértve az Egyéb Szervezeti Egységeket)">KSZE</span>/Transzlációs Medicina Központ</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10085993"><a href="/gui2/?type=authors&mode=browse&sel=10085993" target="_blank">Paraskevopoulos Panagiotis (<span class="authorship-author-name">Paraskevopoulos Panagiotis</span> <span class="authorAux-mtmt"> Radiology</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Központi Szervezeti Egységek (beleértve az Egyéb Szervezeti Egységeket)">KSZE</span>/Transzlációs Medicina Központ</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Schnabel Tamás </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10064235"><a href="/gui2/?type=authors&mode=browse&sel=10064235" target="_blank">Erőss Bálint (<span class="authorship-author-name">Erőss Bálint Mihály</span> <span class="authorAux-mtmt"> Gasztroenterológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/Pankreász Betegségek Intézete; <span title="Semmelweis Egyetem">SE</span>/<span title="Központi Szervezeti Egységek (beleértve az Egyéb Szervezeti Egységeket)">KSZE</span>/Transzlációs Medicina Központ; <span title="Pécsi Tudományegyetem">PTE</span>/<span title="Általános Orvostudományi Kar">ÁOK</span>/Transzlációs Medicina Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10002629"><a href="/gui2/?type=authors&mode=browse&sel=10002629" target="_blank">Hegyi Péter (<span class="authorship-author-name">Hegyi Péter</span> <span class="authorAux-mtmt"> Gasztroenterológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/Pankreász Betegségek Intézete; <span title="Semmelweis Egyetem">SE</span>/<span title="Központi Szervezeti Egységek (beleértve az Egyéb Szervezeti Egységeket)">KSZE</span>/Transzlációs Medicina Központ; <span title="Pécsi Tudományegyetem">PTE</span>/<span title="Általános Orvostudományi Kar">ÁOK</span>/Transzlációs Medicina Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10023767"><a href="/gui2/?type=authors&mode=browse&sel=10023767" target="_blank">Lenti Katalin^** (<span class="authorship-author-name">Földvári-Nagy Lászlóné Lenti Katalin</span> <span class="authorAux-mtmt"> élettan-biokémia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Egészségtudományi Kar">ETK2007</span>/Morfológiai és Fiziológiai Tanszék</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10045537"><a href="/gui2/?type=authors&mode=browse&sel=10045537" target="_blank">Földvári-Nagy László ✉ (<span class="authorship-author-name">Földvári-Nagy László</span> <span class="authorAux-mtmt"> biológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Egészségtudományi Kar">ETK2007</span>/Morfológiai és Fiziológiai Tanszék</span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;35663269" target="_blank">Comparative effectiveness of different therapies for Clostridioides difficile infection in adults: a systematic review and network meta-analysis of randomized controlled trials</a></div> <div> <span class="journal-title">LANCET REGIONAL HEALTH - EUROPE</span> <span class="journal-issn">( <a target="_blank" href="https://portal.issn.org/resource/ISSN/2666-7762">2666-7762</a>)</span>: <span class="journal-volume">49</span> <span class="page"> Paper 101151. 14 p. </span> <span class="year">(2025)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_GOLD" title=" Gold "> <a style="color:blue" title="10.1016/j.lanepe.2024.101151" target="_blank" href="https://doi.org/10.1016/j.lanepe.2024.101151"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="001435988400001" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/001435988400001"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="85211330692" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85211330692"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="39989875" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=39989875&dopt=Abstract"> PubMed </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Health Policy&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;D1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Internal Medicine&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;D1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Oncology&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;D1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Public Health, Environmental and Occupational Health&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;D1</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="Nyilvános idézőközlemények összesen, említések nélkül" class="citingPub-count">Nyilvános idéző összesen: 24</span> | Független: 23 | Függő: 1 | Nem jelölt: 0 | WoS jelölt: 20 | Scopus jelölt:&nbsp;22 | WoS/Scopus jelölt:&nbsp;23 | DOI jelölt:&nbsp;24 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;35663269&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 3 </a> </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 35663269</span> | <span class="status-data status-VALIDATED"> Egyeztetett </span> Forrás Idéző | <span class="type-subtype">Folyóiratcikk ( Összefoglaló cikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">kézi felvitel</span> </div> <div class="notDuplums"><a target="_blank" href="/api/publication/35663269/notduplums">1 Nem duplumnak jelölés</a> </div> <div class="lastModified">Utolsó módosítás: 2026.06.18. 19:18 Milánkovics Róbert (PTE ÁOK admin 4) </div> <pre class="comment" style="margin-top: 0; margin-bottom: 0;"><u>Megjegyzés</u>: Funding Agency and Grant Number: Semmelweis University Funding text: Acknowledgements The authors gratefully acknowledge Semmelweis University for the support, which made the research and publication of the results possible.</pre> </div></div>